{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:17:12Z","timestamp":1773260232082,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,1,5]],"date-time":"2012-01-05T00:00:00Z","timestamp":1325721600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1007\/s10822-011-9540-z","type":"journal-article","created":{"date-parts":[[2012,1,4]],"date-time":"2012-01-04T13:04:59Z","timestamp":1325682299000},"page":"267-277","source":"Crossref","is-referenced-by-count":17,"title":["Development of energetic pharmacophore for the designing of 1,2,3,4-tetrahydropyrimidine derivatives as selective cyclooxygenase-2 inhibitors"],"prefix":"10.1007","volume":"26","author":[{"given":"Deepak","family":"Lokwani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reecha","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santosh","family":"Mokale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Padma","family":"Shastry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devanand","family":"Shinde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,1,5]]},"reference":[{"key":"9540_CR1","doi-asserted-by":"crossref","first-page":"12013","DOI":"10.1073\/pnas.91.25.12013","volume":"91","author":"K Seibert","year":"1994","unstructured":"Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, Lee L, Isakson P (1994) Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 91:12013\u201312017","journal-title":"Proc Natl Acad Sci USA"},{"key":"9540_CR2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0090-6980(02)00024-2","volume":"68\u201369","author":"T Tanabe","year":"2002","unstructured":"Tanabe T, Tohnai N (2002) Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat 68\u201369:95\u2013114","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"9540_CR3","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000318746","volume":"83","author":"C Sakamoto","year":"2011","unstructured":"Sakamoto C, Soen S (2011) Efficacy and safety of the selective cyclooxygenase-2 inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in Japan. Digestion 83:108\u2013123","journal-title":"Digestion"},{"key":"9540_CR4","doi-asserted-by":"crossref","unstructured":"Lanas A (2010) A review of the gastrointestinal safety data\u2014a gastroenterologist\u2019s perspective. Rheumatology 49:ii3\u2013ii10","DOI":"10.1093\/rheumatology\/keq058"},{"key":"9540_CR5","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","volume":"352","author":"RS Bresalier","year":"2005","unstructured":"Bresalier RS, Sandler RS, Quan H et al (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092\u20131102","journal-title":"N Engl J Med"},{"key":"9540_CR6","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1126\/science.306.5695.384","volume":"306","author":"J Couzin","year":"2004","unstructured":"Couzin J (2004) Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Science 306:384\u2013385","journal-title":"Science"},{"key":"9540_CR7","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.jacc.2008.08.041","volume":"52","author":"LA Garc\u00eda Rodr\u00edguez","year":"2008","unstructured":"Garc\u00eda Rodr\u00edguez LA, Tacconelli S, Patrignani P (2008) Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 52:1628\u20131636","journal-title":"J Am Coll Cardiol"},{"key":"9540_CR8","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1136\/ard.2007.076760","volume":"8","author":"NJ Goodson","year":"2009","unstructured":"Goodson NJ, Brookhart AM, Symmons DPM, Silman AJ, Solomon DH (2009) Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis 8:367\u2013372","journal-title":"Ann Rheum Dis"},{"key":"9540_CR9","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.tetlet.2004.12.055","volume":"46","author":"LR Reddy","year":"2005","unstructured":"Reddy LR, Corey EJ (2005) Facile air oxidation of the conjugate base of rofecoxib (VioxxTM), a possible contributor to chronic human toxicity. Tetrahedron Lett 46:927\u2013929","journal-title":"Tetrahedron Lett"},{"key":"9540_CR10","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)16894-3","volume":"364","author":"ME Farkouh","year":"2004","unstructured":"Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ et al (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), cardiovascular outcomes: Randomized controlled trial. Lancet 364:675\u2013684","journal-title":"Lancet"},{"key":"9540_CR11","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1056\/NEJMp048288","volume":"351","author":"GA Fitzgerald","year":"2004","unstructured":"Fitzgerald GA (2004) Coxibs and cardiovascular disease. New Engl J Med 351:1709\u20131711","journal-title":"New Engl J Med"},{"key":"9540_CR12","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1124\/dmd.107.019018","volume":"36","author":"Y Li","year":"2008","unstructured":"Li Y, Slatter JG, Zhang Z, Li Y, Doss GA, Braun MP, Stearns RA, Dean DC, Baillie TA, Tang W (2008) In vitro metabolic activation of lumiracoxib in rat and human liver preparations. Drug Metab Dispos 36:469\u2013473","journal-title":"Drug Metab Dispos"},{"key":"9540_CR13","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/j.bmc.2007.11.079","volume":"16","author":"A Orjales","year":"2008","unstructured":"Orjales A, Mosquera R, L\u00f3pez B, Olivera R, Labeaga L, N\u00fa\u00f1ez MT (2008) Novel 2-(4-methylsulfonylphenyl)pyrimidine derivatives as highly potent and specific COX-2 inhibitors. Bioorg Med Chem 16:2183\u20132199","journal-title":"Bioorg Med Chem"},{"key":"9540_CR14","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.3390\/molecules15031882","volume":"15","author":"MS Mohamed","year":"2010","unstructured":"Mohamed MS, Awad SM, Sayed AI (2010) Synthesis of certain pyrimidine derivatives as antimicrobial agents and anti-inflammatory agents. Molecules 15:1882\u20131890","journal-title":"Molecules"},{"key":"9540_CR15","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1016\/j.ejmech.2010.08.022","volume":"45","author":"O Alam","year":"2010","unstructured":"Alam O, Khan SA, Siddiqui N, Ahsan W, Verma SP, Gilani SJ (2010) Antihypertensive activity of newer 1,4-dihydro-5-pyrimidine carboxamides: Synthesis and pharmacological evaluation. Eur J Med Chem 45:5113\u20135119","journal-title":"Eur J Med Chem"},{"key":"9540_CR16","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1016\/j.bmcl.2011.03.062","volume":"21","author":"RH Tale","year":"2011","unstructured":"Tale RH, Rodge AH, Hatnapure GD, Keche AP (2011) The novel 3,4-dihydropyrimidin-2(1H)-one urea derivatives of N-aryl urea: synthesis, anti-inflammatory, antibacterial and antifungal activity evaluation. Bioorg Med Chem Lett 21:4648\u20134651","journal-title":"Bioorg Med Chem Lett"},{"key":"9540_CR17","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1016\/j.bmcl.2010.06.058","volume":"20","author":"SN Mokale","year":"2010","unstructured":"Mokale SN, Shinde SS, Elgire RD, Sangshetti JN, Shinde DB (2010) Synthesis and anti-inflammatory activity of some 3-(4,6-disubtituted-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl) propanoic acid derivatives. Bioorg Med Chem Lett 20:4424\u20134426","journal-title":"Bioorg Med Chem Lett"},{"key":"9540_CR18","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.bmcl.2004.01.039","volume":"14","author":"SS Bahekar","year":"2004","unstructured":"Bahekar SS, Shinde DB (2004) Synthesis and anti-inflammatory activity of some [4,6-(4-substituted aryl)-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl]-acetic acid derivatives. Bioorg Med Chem Lett 14:1733\u20131736","journal-title":"Bioorg Med Chem Lett"},{"key":"9540_CR19","first-page":"223","volume":"53","author":"SS Bahekar","year":"2003","unstructured":"Bahekar SS, Shinde DB (2003) Synthesis and anti-inflammatory activity of some (2-amino-6-(4-substituted aryl)-4-(4-substitutedphenyl)-1,6-dihydropyrimidine-5-yl)-acetic acid derivatives. Acta Pharm 53:223\u2013229","journal-title":"Acta Pharm"},{"key":"9540_CR20","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1021\/ci100409y","volume":"51","author":"S Durdagi","year":"2011","unstructured":"Durdagi S, Duff HJ, Noskov Su (2011) Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain. J Chem Inf Model 51:463\u2013474","journal-title":"J Chem Inf Model"},{"key":"9540_CR21","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s00894-008-0350-8","volume":"14","author":"M Chopra","year":"2008","unstructured":"Chopra M, Gupta R, Gupta S, Saluja D (2008) Molecular modeling study on chemically diverse series of cyclooxygenase-2 selective inhibitors: generation of predictive pharmacophore model using catalyst. J Mol Model 14:1087\u20131099","journal-title":"J Mol Model"},{"key":"9540_CR22","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1021\/jm051256o","volume":"49","author":"RA Friesner","year":"2006","unstructured":"Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49:6177\u20136196","journal-title":"J Med Chem"},{"key":"9540_CR23","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1021\/ci900212v","volume":"49","author":"NK Salam","year":"2009","unstructured":"Salam NK, Nuti R, Sherman W (2009) Novel method for generating structure-based pharmacophores using energetic analysis. J Chem Inf Model 49:2356\u20132368","journal-title":"J Chem Inf Model"},{"key":"9540_CR24","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10822-009-9268-1","volume":"23","author":"K Loving","year":"2009","unstructured":"Loving K, Salam NK, Sherman W (2009) Energetic analysis of fragment docking and application to structure-based pharmacophore hypothesis generation. J Comput Aided Mol Des 23:541\u2013554","journal-title":"J Comput Aided Mol Des"},{"key":"9540_CR25","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1007\/BF02980259","volume":"30","author":"AM Ali","year":"2007","unstructured":"Ali AM, Saber GE, Mahfouz NM, EI-Gendy MA, Radwan AA, Hamid MA (2007) Synthesis and three-dimensional qualitative structure selectivity relationship of 3,5-disubstituted-2,4-thiazolidinedione derivatives as COX2 inhibitors. Arch Pharm Res 30:1186\u20131204","journal-title":"Arch Pharm Res"},{"key":"9540_CR26","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S1388-1981(99)00147-X","volume":"1441","author":"RM Garavito","year":"1999","unstructured":"Garavito RM (1999) The cyclooxygenase isoforms: structural insights into the conversion of arachidonic acid to prostaglandins. Biochim Biophys Acta 1441:278\u2013287","journal-title":"Biochim Biophys Acta"},{"key":"9540_CR27","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0223-5234(03)00115-6","volume":"38","author":"C Charlier","year":"2003","unstructured":"Charlier C, Michaux C (2003) Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. Eur J Med Chem 38:645\u2013659","journal-title":"Eur J Med Chem"},{"key":"9540_CR28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/protein\/8.2.127","volume":"8","author":"AC Wallace","year":"1995","unstructured":"Wallace AC, Laskowski RA, Thornton JM (1995) LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng 8:127\u2013134","journal-title":"Protein Eng"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-011-9540-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10822-011-9540-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-011-9540-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T19:52:23Z","timestamp":1561146743000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10822-011-9540-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,5]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["9540"],"URL":"https:\/\/doi.org\/10.1007\/s10822-011-9540-z","relation":{},"ISSN":["0920-654X","1573-4951"],"issn-type":[{"value":"0920-654X","type":"print"},{"value":"1573-4951","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,5]]}}}